Objective To determine whether pharmacologic treatment for neonatal abstinence syndrome
(NAS) is associated with changes in DNA methylation (DNAm) of the mu-opioid receptor …

Objective Neonatal abstinence syndrome (NAS) from in utero opioid exposure is highly
variable with genetic factors appearing to play an important role. Epigenetic changes in …

Neonatal abstinence syndrome (NAS) due to in‐utero opioid exposure has significant
variability of severity. Preliminary studies have suggested that epigenetic variation within the …

Neonatal abstinence syndrome (NAS) due to in-utero opioid exposure is a growing
epidemic with significant variability in clinical presentation and severity. Currently, NAS …

Background There is significant variability in the severity of neonatal abstinence syndrome
(NAS) due to in-utero opioid exposure. We wanted to determine if single nucleotide …

Objective To investigate whether in utero opioid exposure, which has been linked to adverse
neurodevelopmental and social outcomes, is associated with altered DNA methylation of …

Background and Objectives There is significant variability in severity of neonatal abstinence
syndrome (NAS) due to in utero opioid exposure. Our previous study identified single …

Significant variability has been observed in the development and severity of neonatal
abstinence syndrome (NAS) among neonates exposed to prenatal opioids. Since maternal …

Background Neonatal abstinence syndrome (NAS) in infants of methadone-maintained
opioid-dependent (MMOD) mothers cannot be predicted in individual cases. We …

Neonatal abstinence syndrome (NAS) is a constellation of signs of withdrawal occurring
after birth following in utero exposure to licit or illicit opioids. Despite significant research and …